Document:

Amendment to License Agreement

 Exhibit 10.87 
 AMENDMENT TO LICENSE AGREEMENT 
 This Amendment (the “Amendment”) is made and entered into as of
October 31, 2004 to the License Agreement (the “Agreement”) made and entered into as of August 1, 2003, as amended as of December 1, 2003 and May 4, 2004, by and between Senetek PLC, an English corporation with its
corporate headquarters located at 620 Airpark Road, Napa, California 94558 (“Senetek”), and Valeant Pharmaceuticals International, a Delaware corporation with its corporate headquarters located at 3300 Hyland Avenue, Costa Mesa,
California 92626 (“Licensee”). Capitalized terms used herein and not otherwise defined are used with the meanings ascribed to them in the Agreement. 
 In consideration of the mutual promises, covenants, and conditions set forth below, the parties agree as follows: 
 1. Minimum Payments. Section 3.12 of the Agreement is hereby amended to read in its entirety as follows: 
 “3.12 Minimum Payments. To maintain the Exclusivity Right with respect to Canada and the United States of America, during the second Contract
Year Licensee’s payments of Royalties due pursuant to Section 3.11 and Base Price due pursuant to Section 3.1 (collectively, “Payments”) shall be not less than *** and to maintain the Exclusivity Right with respect to the
European Union and Australia, during the second Contract Year Licensee’s Payments shall be not less than *** (collectively, the “Minimum Payments”), provided however that if Licensee makes Payments during the second
Contract Year with respect to Products sold in all territories equal to or exceeding ***, it shall maintain the Exclusivity Right in the United States of America, Canada, the European Union, and Australia, and if Licensee makes Payments with respect
to Products sold in all territories equal to or exceeding *** but less than *** it shall maintain the Exclusivity Right in the United States of America and Canada. 
 2. Adjustments to Minimum Payments. Section 3.13 of the Agreement is hereby amended to read in its entirety as follows: 
 “3.13 Adjustments to Minimum Payments. 
 (i) Within sixty (60) days after the end of the second and each subsequent
Contract Year, Senetek and Licensee shall negotiate in good faith with respect to the Minimum Payments to be required for the next Contract Year in order to maintain the Exclusivity Right in Canada and the United States of America, provided
that if the parties fail to reach agreement with respect thereto by the end of the first Calendar Quarter of such next Contract Year, then the Minimum Payments applicable to such next Contract Year in order to maintain the Exclusivity Right in
Canada and the United States of America shall be equal to the Minimum Payments applicable to the Contract Year just completed. 
 (ii) Within
sixty (60) days after the end of the second and each subsequent Contract Year, Senetek and Licensee shall negotiate in good faith with respect to the Minimum Payments to be required for the next Contract Year in order to maintain the
Exclusivity Right in the European Union and Australia, provided that if the parties fail to reach agreement with respect thereto by the end of the first Calendar Quarter of such next Contract Year, then the Minimum Payments applicable to such
next Contract Year in order to maintain the Exclusivity Right in the European Union and Australia shall be equal to the Minimum Payments applicable to the Contract Year just completed. 
 Notwithstanding the foregoing, after such time as the aggregate Royalties payable pursuant to clause (A) of Section 3.1l(ii) at the rate of ***
total *** and the 
 *** Confidential treatment has been requested 

 royalty rate is increased to ***, the Minimum Payment to maintain the Exclusivity Right in the United States of America
and Canada shall be *** and the Minimum Payment to maintain the Exclusivity Right in the European Union and Australia shall remain *** (each subject to aggregation as described in the proviso to Section 3.12 above).” 
 3. No Further Amendments. Except as amended by this Amendment, the Agreement shall not be deemed to have been modified or affected hereby in any
respect, and as amended hereby the Agreement shall remain in full force and effect according to its terms. 
 To evidence this Amendment, the
parties have caused their duly authorized representatives to execute this Amendment as of the date first set forth above. 
  

					
		 	 VALEANT PHARMACEUTICALS
INTERNATIONAL

			
		 	By:	 	 /s/ [ILLEGIBLE]

		 	Name:	 	[ILLEGIBLE]
		 	Title:	 	PRESIDENT
		
		 	SENETEK PLC
			
		 	By:	 	 /s/ FRANK J. MASSINO

		 	Name:	 	FRANK J. MASSINO
		 	Title:	 	CEO

 *** Confidential treatment has been requestedAmended and restated agreement between Senetek PLC and Signet Laboratories

 Exhibit 10.90 
 AGREEMENT 
 This Agreement (“Agreement”), dated as of January 1, 2005 and
effective April 1st 2004, is between Senetek PLC, a United Kingdom company whose principal office is located at
620 Airpark Road, Napa, California 94558 (hereinafter referred to as ‘Senetek’), and Signet Laboratories, Inc., a Delaware corporation having its principal place of business at 180 Rustcraft Road, Dedham, Massachusetts 02026 (hereinafter
referred to as “Signet”). 
 WITNESSETH THAT: 
 WHEREAS, Senetek is a party to an Agreement by and between Research Foundation for Mental Hygiene, Inc. (hereinafter referred to as RFMH) and Senetek, dated by Senetek July 21, 1994 and dated by RFMH
July 12, 1994, as amended by Amendment #1 dated by Senetek August 1, 1995 and dated by RFMH July 28, 1995, and Amendment #2 dated by Senetek December 12, 2000 and dated by RFMH November 1, 2000, copies of which are attached
as Exhibit A (hereinafter referred to as the “Basic Agreement/License”); 
 WHEREAS, in connection with Amendment #3 dated
May 6, 2004 by Senetek and May 10, 2004 by RFMH, Senetek has entered into an extension until September 30th 2005 to the Basic Agreement/License in the form annexed as Exhibit B (the “Extension”); 
 WHEREAS, pursuant to
the Basic Agreement/License Senetek was granted a ten-year exclusive worldwide license to certain RFMH cell lines, to wit: 
 1. Those certain
cell lines designated “4G8” and “6E10” more particularly described in the Basic Agreement/License; 
 2. The monoclonal
antibody designated “5-25 Reactive to PHF” more particularly described in an Agreement dated by Senetek August 1, 1995 and dated by RFMH July 28, 1995, said Agreement being attached as “Appendix A-1” to the Basic
Agreement/License; 
 3. Those certain cell lines designated “3-39 Reactive to PHF” and 3F4 Reactive to Prion PrP (human and
hamster)” more particularly described in an Agreement dated by Senetek August 30, 1995 and dated by RFMH August 22, 1995, said Agreement being attached as “Appendix A-2” to the Basic Agreement/License; 
 4. Those certain cell lines more particularly described in an Agreement dated by Senetek July 2, 2001 and dated by RFMH July 11, 2001, said
Agreement being attached as “Appendix A-3” to the Basic Agreement/License; and 
 5. Any cell lines hereafter added to the Basic
Agreement/License by agreement of the parties thereto following agreement of the parties to this Agreement and set forth in an Appendix thereto, e.g. “Appendix A-4” (collectively, the “Cell Lines”). 
  

 1 

 WHEREAS, the Basic Agreement/License and the Extension grant Senetek an exclusive worldwide license to
manufacture, package, promote and sell those Cell Line products listed on Exhibit C attached hereto, to wit: the monoclonal antibodies produced in any form by using the Cell Lines, including but not limited to pure, Fab fragment, ascites fluid,
tissue culture fluid, modified or conjugated (i. e. enzymes, biotin, florescent or any other form), and new Cell Line products which are not listed on Appendices A-1 to A-3 to the Basic Agreement/License but are hereafter added to the Basic
Agreement/License by agreement of the parties thereto following agreement of the parties to this Agreement and are set forth in an Appendix thereto, e.g. “Appendix A-4” (hereinafter the “Cell Line Products”); 
 WHEREAS, Senetek and Signet are parties to a Production and Marketing Agreement dated and effective August 15, 2000, as amended (the “Original
Agreement”), pursuant to which Signet has manufactured and distributed antibodies derived from the Cell Lines; and 
 WHEREAS, Senetek
and Signet desire to supersede the Original Agreement effective April 1, 2004 with this Agreement. 
 NOW, THEREFORE, in consideration
of the mutual covenants herein recited, the parties hereby agree as follows: 
 1. Grant 
 1.1 Right to Manufacture, Package, Promote, and Sell. Upon the terms and conditions set forth herein, Senetek hereby grants to Signet a worldwide
exclusive right to manufacture, package, promote and sell the Cell Line Products in accordance with the terms and conditions set forth herein and subject to and in accordance with the terms of the Basic Agreement/License and the Extension as from
time to time in effect, provided that Signet acknowledges RFMH’s right under the Basic Agreement/License to possess, culture and employ the Cell Lines and the antibodies produced therefrom for its own scientific purposes including
transferring necessary amounts of antibodies (but not Cell Lines) to research collaborators of RFMH or the Institute for Basic Research (“IBR”) free of all charges other than shipping and handling costs, pursuant to appropriately
restrictive Material Transfer Agreements specifying, as provided in the Basic Agreement/License, that such collaborators “shall be bound by an obligation to use these antibodies only for . . scientific collaboration with RFMH”. Signet
shall have the right to terminate this Agreement as provided in Section 7.l (ii) if RFMH breaches or omits to perform any of its obligations under the Basic Agreement/License and fails to cure the same as provided in Section 7.l(ii).
Senetek shall use best efforts to obtain from RFMH and provide to Signet on a quarterly basis a list of all research collaborators to which Cell Line Products have been so transferred. 
 1.2 Acceptance by Signet. Signet hereby accepts the foregoing grant of worldwide exclusive rights to manufacture, package, promote and sell the
Cell Line Products subject to and in accordance with Section 1.1. 
 1.3 Polyclonal Antibodies. The parties hereto acknowledge that
polyclonal antibodies and derivatives and intermediates produced by IBR (“Polyclonals”) are not Cell Line Products covered by the Basic Agreement/License but that prior to the date hereof certain Polyclonals were supplied to Signet by IBR,
certain of which remain in Signet’s inventory. The parties agree that Section 3 of this Agreement shall apply to all such Polyclonals supplied by IBR to Signet prior to the date hereof as if they were Cell Line Products but that any
Polyclonals to be supplied by RFMH or IBR after the date hereof will be supplied pursuant to Material Transfer Agreements between RFMH and Senetek in such form as may be agreed by the parties thereto and that no portion of this Agreement shall apply
thereto. 
  

 2 

 1.4 Quarterly Meetings. Senetek shall use its best efforts to arrange for quarterly in person or
telephonic meetings between representatives of RFMH, Senetek and Signet to discuss the progress of the business, new Cell Line Products that may be available and other appropriate subjects, including the tracking and monitoring of Cell Line Product
transfers. Signet shall have the right to terminate this Agreement as provided in and subject to the limitations of Section 7.1(ii) if such quarterly meetings are not held. 
 1.5 Elimination of Exclusivity on Cell Lines Covered by the Agreement. Signet shall be responsible for remitting to Senetek within thirty
(30) days after the end of each calendar year commencing with calendar year 2005 the annual maintenance fees provided for in the Basic Agreement/License (which are non-refundable but fully creditable against royalties remitted to RFMH) to the
extent its Net Sales during such calendar year do not generate sufficient royalties payable to RFMH to achieve full credit therefor, provided that if Signet wishes to eliminate its exclusivity with respect to any Cell Lines covered by this
Agreement, it may so notify Senetek in writing, whereupon Senetek shall provide such notice to RFMH and Signet’s obligation to pay the annual maintenance fee provided for in the Basic Agreement/License with respect thereto shall cease effective
as of January 1 of the next succeeding year. Signet shall have until April 30, 2005 to so eliminate exclusivity with respect to any Cell Lines covered by this Agreement as of the date hereof and shall have six (6) months from delivery of
any new Cell Line to so eliminate exclusivity with respect to such new Cell Line, provided that if Signet determines after having so eliminated its exclusivity with respect to any Cell Line that it wishes to again have exclusivity with
respect to such Cell Line, Senetek shall promptly so notify RFMH in writing and RFMH shall reinstate such exclusivity (unless it has theretofore entered into negotiations to license or licensed such Cell Line to a third party) whereupon
Signet’s obligation with respect to payment of the annual maintenance fee therefore shall be reinstated. With respect to any Cell Line as to which exclusivity has been eliminated, Signet shall have the right to continue to manufacture, package,
promote and sell such Cell Line upon all of the terms of this Agreement other than the exclusivity provided for herein, provided that if RFMH gives thirty (30) days written notice to Senetek to return any Cell Line(s) as to which
exclusivity has been eliminated, Senetek shall immediately provide such notice to Signet and termination of nonexclusive rights to such Cell Line(s) shall become effective on the thirtieth (30th) day following such notice to Signet, provided
further that Signet may complete any sale for which it had a firm order on the date or its receipt of such notice, subject to the terms of this Agreement. 
 1.6 Not a License. This grant shall not be construed as a license or sub-license, by implication or otherwise, of any rights to which Senetek is licensed in accordance with the Basic Agreement/License.

 2. Term of Agreement 
 The term of this
Agreement shall be contemporaneous with the Basic Agreement/License and the Extension, as the same may be extended from time to time, unless terminated as hereinafter provided. 
 3. Sharing of Revenues 
 3.1 From the first *** of annual Net Sales (including calendar 2004) revenues
received by Signet from sales of Cell Line Products, Signet shall retain *** of such revenues. The *** remainder of such revenues shall be remitted to Senetek. Senetek shall be responsible for all fees due to RFMH in accordance with the Basic
Agreement/License and Extension. 
 3.2 From annual Net Sales (including calendar 2004) revenues in excess of *** received by Signet from
sales of Cell Line Products, Signet shall retain *** of such revenues in excess of ***. The *** remainder of such revenues shall be remitted to Senetek. Senetek shall be responsible for all fees due to RFMH in accordance with the Basic
Agreement/License and Extension. 
 *** Confidential treatment has been requested 
  

 3 

 3.3 Signet shall be entitled to credit against the amounts remitted to Senetek with respect to each of
the second, third and fourth calendar quarters of 2004 an amount equal to one-third of the amount by which the payment made by Signet to Senetek pursuant to the Original Agreement for the first calendar quarter of 2004 exceeded the amount which
would have been payable by Signet to Senetek under this Agreement, if it had been effective from January 1, 2004. 
 3.4 In the event
that Signet’s aggregate Net Sales of Cell Line Products for any calendar year are less than *** Signet shall remit to Senetek, together with the payment due for the fourth calendar quarter of such year, an amount equal to *** of the amount by
which Signet’s Net Sales are less than such amount. 
 3.5 “Net Sales” means Signet’s gross sales revenues of all Cell
Line Products (provided that in the case of kits comprised of Cell Line Products and/or Polyclonals as to which Section 3 of this Agreement applies as provided in Section 1.3 (“Royalty-bearing Products”) and other
materials that are not Royalty-bearing Products, “Net Sales” prior to January 1, 2005 means *** of gross kit sales and effective January 1, 2005 means *** of the gross sales revenues of such kits) less (i) when billed
separately, import, export, excise and sales taxes, and customs duties and freight out, and (ii) sales returns, allowances and discounts given in the ordinary course of Signet’s business (or, in the case of kits covered by the above
proviso, *** of the amounts in (i) and/or (ii)). Attached as Schedule I is a listing of all currently marketed kits and other such products of Signet setting forth, as to each, the quantity of the Royalty-bearing Products included
therein and the gross sale price thereof. Signet shall provide to Senetek an updated Schedule I annually within thirty (30) days after the end of each calendar year beginning with calendar year 2005. 
 3.6 To the extent that Signet desires to receive from RFMH any photomicrographs or other scientific data for the marketing of Cell Line Products, it shall
provide a request for quote to Senetek for forwarding to RKMH, and will respond to RFMH’s quote in writing noting its approval and willingness to proceed on the basis quoted. RFMH shall submit a detailed invoice to Senetek for the reasonable
costs incurred by RFMH/IBR for any photomicrographs or other scientific data requested by Signet for the marketing of Cell Line Products consistent with such quote, and Signet shall remit to Senetek the amount of such invoice for payment to RFMH.
Photomicrographs or other scientific data necessary for the production of Cell Line Products shall be supplied to Signet without mark-up of its actual reasonable costs. 
 3.7 If Signet desires assistance from the scientific or other staff of RFMH or IBR in connection with Signet’s performance of this Agreement, including product development, marketing, customer relations, testing
of Cell Line Products produced by Signet or the like, it shall submit to Senetek for forwarding to RFMH a proposal setting forth the services requested. Senetek shall use best efforts promptly to obtain from RFMH a proposal for the furnishing of
such services and shall promptly forward it to Signet, and if Signet accepts the per diem or other compensation proposed by RFMH to be charged to Signet, Senetek shall use best efforts to cause RFMH to provide such services, subject to the
requirements of its and IBR’s regular activities. 
 4. Reports 
 4.1 Reports Signet agrees to deliver to Senetek within thirty (30) days after the expiration of each calendar quarter beginning with the
calendar quarter commencing July 1, 2004 (i) an accounting in writing setting forth the calculation of Net Sales for such quarter and (ii) an accounting for specific expenses incurred by Signet in developing, promoting and marketing
Cell Line Products during such quarter, as agreed by the parties. In addition, Signet agrees to deliver to Senetek within forty-five (45) days after the end of each calendar year commencing with calendar year 2004 an accounting in writing
setting forth (a) the unit sales for each Cell Line Product sold during the calendar year reported upon, (b) each shipment of Cell Line Products, including customer, and (c) the total Net Sales of Cell Line Products to each purchaser
other than an end user research institution, indicating the pricing allowed to each such customer. Senetek agrees that the customer information provided is confidential as per Section 8(ii) and cannot be used competitively or transferred to any
person except as may be necessary for the furtherance of this Agreement. 
 *** Confidential treatment has been requested 

 

 4 

 4.2 Records and Audits Signet shall keep a true and exact record in connection with the accounting
provided herein, and Senetek shall have the right once each calendar year beginning with the first report to appoint at no cost to Signet an independent certified public accountant, to whom Signet has no reasonable objection, who, during the regular
business hours of Signet may examine the accounts and records of Signet insofar as they relate to net sales of Cell Line Products for a period not more than two (2) years preceding the date of inspection, for the sole purpose of verifying the
correctness of the reporting provided for in Section 4.2 and Signet’s compliance with the term of this Agreement, and not for any other purpose. Said accountant shall be under an obligation of secrecy not to disclose any information (s)he
learns except (s)he may disclose to Senetek any information, which relates solely to the accuracy of reports and payments under this Agreement and Signet’s compliance with this Agreement. 
 5. Payments 
 5.1 Payments Payments to Senetek
shall be due and payable thirty (30) days after the expiration of each calendar quarter, except that Signet may elect to make such payments in three equal installments thirty (30), sixty (60) and ninety (90) days after quarter end for
those payments related to annual Net Sales up to ***. If Signet elects to make such payment in three equal installments, Signet will be charged interest at an annual rate of *** with interest starting to accrue thirty-one (31) days after
quarter end. Payments due for Net Sales in excess of *** will be due thirty (30) days after quarter end. 
 5.2 Currencies All
payments payable hereunder to Senetek shall be payable in United States Dollars (USD). If foreign exchange is freely available and remittance of the payments provided herein is not otherwise prohibited, all royalties due to Senetek hereunder as a
result of sales in countries foreign to the United States shall be converted (for the purpose only of calculation of such royalties) into its equivalent in USD at the foreign exchange rate for such foreign funds as reported in the Wall Street
Journal, at the close of business on the last business day of the quarterly reporting period. 
 6. Representations, Warranties and Agreements

 6.1 Signet 
 (i) Signet
agrees that Signet shall devote its faithful, diligent and best efforts to distribute, market, promote and sell the Cell Line Products, and maintain and enhance the good will of the Cell Line Products worldwide. 
 (ii) Signet warrants and represents to Senetek that it is not, and shall not hold itself out as, the representative, agent, servant or employee of
Senetek, RFMH, IBR or the State of New York for any purpose. This Agreement creates no relationship of joint venture, partnership, limited partnership, or agency between the parties. 
 (iii) Signet represents and warrants that the execution of this Agreement by Signet has been duly authorized by all necessary corporate action of Signet
and constitutes the valid and binding obligation of Signet. The execution of this Agreement by Signet and the consummation of the transactions contemplated hereby does not conflict with or result in a default under or breach of,
(1) Signet’s Articles of Incorporation or By-laws or other organizational documents; (2) any agreement, indenture, mortgage, contract or instrument to which Signet is bound or by which any of its properties or assets is subject;
(3) any order, writ, injunction, decree or judgment of any court or governmental agency applicable to Signet or to which any of its assets is bound; or (4) any law or regulation applicable to Signet or by which any of its assets is bound.

 (iv) Signet acknowledges that the Cell Line Products, (1) have been represented by Senetek as being the sole property and confidential
information of RFMH; (2) are subject to confidentiality requirements under the Basic Agreement/License which requirements also bind Signet; and (3) may be transferred only back to Senetek or RFMH in accordance with the terms and
requirements of the Basic Agreement/License and Extension. 
 *** Confidential treatment has been requested 
  

 5 

 (v) Signet agrees that the Cell Line Products are to be produced and sold solely for in vitro
scientific research and diagnostic use directly to end user research institutions except as RFMH may otherwise approve. Annexed as Schedule II is a list of all non-end users to which Signet has made sales of Cell Line Products since
January 1, 2004, which Signet represents are either (a) distributors that service end-users outside of North America which cannot cost effectively be sold direct by Signet, (b) North American distributors that service only end-users
which cannot cost effectively be serviced by Signet, (c) distributors which act as purchasing agents for particular end users, (d) distributors that receive no discount from Signet’s end user sales prices or receive lower discounts
than end users, (e) manufacturers of diagnostic or laboratory equipment or (f) distributor relationships that were transferred to Signet at the time the Original Agreement was executed. On the basis of such representation, RFMH has
approved continued sales to such non-end users so long as they satisfy the above representation. If Signet proposes to make sales of Cell Line Products to any non-end user other than those listed on Schedule II or to any non-end user listed on
Schedule II after it no longer satisfies the above representation, it shall submit to Senetek a proposed revision to Schedule II, Senetek shall promptly submit the same to RFMH for its approval, and Signet shall not make any sales to such non-end
user until receipt from Senetek of written approval by RFMH of such change. Approval shall not be unreasonably withheld by RFMH and its determination shall be supplied to Signet within thirty (30) days of Signet’s submission. 

(vi) Signet agrees to provide to Senetek such information as Senetek may reasonably request in order for Senetek to certify annually to RFMH
Signet’s compliance with the foregoing, including verification of its production and shipping of Cell Line Products. 
 (vii) Signet
agrees not to attempt to enter into or undertake any separate and independent relationship with RFMH or IBR with regard to the Cell Lines or antibodies covered under the Basic Agreement/License and Extension (including any that may be added thereto
by additional Appendix as provided herein) or any Polyclonals produced or furnished by IBR or RFMH, or otherwise compete with Senetek with regard thereto during any period that the Basic Agreement/License remains in effect unless the License to the
Cell Line Products is put out for bid by RFMH. 
 (viii) Signet agrees to indemnify and hold harmless (a) RFMH, the State of New York,
and any of their institutes, employees, representatives, trustees, officers and agents, and (b) Senetek and its officers, directors and employees, against any and all claims of death, illness, personal injury, property damage and improper
business practices arising out of Signet’s manufacture, use or sale of the Cell Line Products, and shall provide to Senetek evidence of its insurance coverage for the foregoing in an amount not less than *** per occurrence and *** annual
aggregate, naming the foregoing as additional insureds, but Signet acknowledges that RFMH and the State of New York shall not be liable for any indirect, special, consequential or other damages whatsoever, whether grounded in fact, strict liability,
contract or otherwise. 
 (ix) Signet agrees to indemnify and hold harmless Senetek from any and all costs, expenses, claims, attorney’s
fees and so forth in regards to acts or omissions on Signet’s part prior to the execution of this Agreement now known or hereafter arising from the Basic Agreement/License and the Extension, including, but not limited to, any and all claims
from RFMH based thereon. 
 6.2 Senetek 
 (i) Senetek warrants and represents to Signet that it is not, and shall not hold itself out as, the representative, agent, servant or employee of Signet for any purpose. This Agreement creates no relationship of joint
venture, partnership, limited partnership, or agency between the parties. 
 (ii) Senetek represents and warrants that the execution of this
Agreement by Senetek has been duly authorized by all necessary corporate action of Senetek and constitutes the valid and binding obligation of Senetek. The execution of this Agreement by Senetek and the consummation of the transactions contemplated
hereby does not 
 *** Confidential treatment has been requested 
  

 6 

 conflict with or result in a default under or breach of, (1) Senetek’s Certificate of
Incorporation or Articles of Association or other organizational documents; (2) any agreement, indenture, mortgage, contract or instrument to which Senetek is bound or by which any of its properties or assets is subject; (3) any order,
writ, injunction, decree or judgment of any court or governmental agency applicable to Senetek or to which any of its assets is bound; or (4) any law or regulation applicable to Senetek or by which any of its assets is bound. 
 (iii) Senetek represents that the Cell Line Products, (1) are the sole property and confidential information of RFMH; (2) are subject to
confidentiality requirements under the Basic Agreement/License and Extension which requirements also bind Senetek; and (3) may be transferred only back to Senetek or RFMH in accordance with the terms and requirements of the Basic
Agreement/License and Extension. 
 (iv) Senetek represents and warrants that it is not in default of any term, provision or condition of the
Basic Agreement/License and the Extension and that its rights thereunder are not encumbered in any manner, and that to the best of Senetek’s knowledge the Cell Line Products are free of any claims for infringement, patent, copyrights and
trademarks of third parties. Senetek also represents and warrants that there is no litigation, claim or assessment pending or threatened against Senetek contesting Senetek’s rights under the Basic Agreement/License and the Extension. Senetek
hereby indemnifies and will hold Signet harmless from any and all costs, expenses, claims, attorney’s fees and so forth in regards to acts or omissions on Senetek’s part prior to the execution of this Agreement now known or hereafter
arising from the Basic Agreement/License and the Extension, including, but not limited to, any and all claims from RFMH based thereon. 
 (v)
Senetek has complied with the terms and conditions of the Basic Agreement/License and the Extension, including but not limited to all notice requirements, and has received all of the necessary approvals from RFMH regarding the execution of this
Agreement, including without limitation under Section 2.4 of the Basic Agreement/License and the Extension, to engage Signet to manufacture, package, promote and sell the Cell Line Products. Evidence of such approval, in form satisfactory to
Signet, will be delivered to Signet simultaneously with the execution of this Agreement. Senetek will deliver forthwith to Signet any and all documents and correspondence received by Senetek from RFMH in regards to the Basic Agreement/License and
the Extension, including, but not limited to, any and all notices of default delivered by RFMH to Senetek. 
 (vi) If Senetek shall fail to
timely cure any default under the Basic Agreement/License or the Extension, then unless Signet’s acts or omissions are the basis of such default Senetek hereby grants to Signet the right to cure any and all such defaults in accordance with the
Basic Agreement/License and the Extension. In the event a default is based on the failure of either party to comply with the terms of the Basic Agreement/License and the Extension and there is an expenditure of time and money by other party to cure
said default, the expending party shall have the right to offset or be reimbursed, as the case may be, any such expenditure from or in addition to future payments due from Signet to Senetek hereunder. 
 7. Termination 
 7. 1 Termination by Signet
This Agreement can be terminated by Signet at any lime upon: 
 (i) two hundred and seventy (270) days written notice by Signet to
Senetek, or 
 (ii) ninety (90) days written notice given by Signet to Senetek within thirty (30) days after Signet becomes aware
that Senetek or RFMH has breached or omitted to perform any action contemplated by this Agreement or by the Basic Agreement/License and the Extension, provided however, that Senetek or RFMH, as the case may be, shall not have cured the same
within such ninety (90) day period. 
 In the event of such termination, Signet agrees to pay to Senetek all amounts due and payable up
to the effective date of such termination. Upon such termination, Signet shall return to Senetek all antibodies, all technical 
  

 7 

 information, Cell Lines and know-how transferred to Signet by Senetek. Signet shall have the right to
sell any Cell Line Products in inventory at the time of such termination for a period not exceeding three months after the effective date of termination under clause (i) or (ii) above provided it shall pay amounts due to Senetek upon the
sale of Cell Lines Products in accordance with Section 3. 
 7.2 Termination by Senetek This Agreement may be terminated by
Senetek if: 
 (i) Signet shall fail to pay any amounts as provided in Section 3 at any time when the same become due, and such failure
shall continue unremedied for ninety (90) days after written notice thereof is sent by Senetek to Signet. 
 (ii) Signet shall at any
time become insolvent or make a general assignment for the benefit of creditors, or if a petition in bankruptcy, or insolvency, or any reorganization shall be commenced by, against or in respect of Signet and shall remain undismissed for more than
ninety (90) days. 
 (iii) In the event of breach or default (for reasons other than failure to pay any amounts due hereunder) by Signet;
provided however, Senetek shall give written notice to Signet of termination by reason of such default within thirty (30) days of its knowledge thereof and such default shall not be cured within ninety (90) days after written
notice. 
 8. Confidentiality 
 (i) Signet
agrees to keep strictly confidential all material and other information of all third parties classified as “Confidential”, including, but not limited to, the terms and conditions of the Basic Agreement/License and the Extension supplied to
Signet by Senetek in connection with its performance under this Agreement and all information concerning RFMH, IBR, Senetek and their respective businesses learned in performing this Agreement. Signet undertakes not to disclose any such
“Confidential’ materials or information to any person except as may be necessary for the furtherance of this Agreement. Signet further agrees to bind its officers and employees, and any agents, representatives or third parties who have
knowledge of or access to such “Confidential” information to a similar obligation of confidentiality. In the event of termination of this Agreement, Signet agrees to return any such “Confidential” materials or information to
Senetek and to cause any person to whom such “Confidential” materials or information has been supplied to do likewise. In compliance with the Basic Agreement/License, Signet agrees that the Cell Lines shall be clearly marked
“Confidential Information”, shall be kept in a secure location, and shall be allowed access only by those individuals who have the need in order to fulfill the terms of this Agreement and are themselves obligated to confidentiality.
Senetek acknowledges that Signet reserves the right to store the Cell Lines and Cell Line Products in a secure third-party facility pursuant to the aforementioned and FDA recommended GMP practices. 
 (ii) Senetek agrees to keep strictly confidential all material and other information of all third parties classified as “Confidential”,
including, but not limited to, the terms and conditions of this Agreement and all information concerning Signet and its business learned in performing this Agreement. Senetek undertakes not to disclose any such “Confidential’ materials or
information to any person except as may be necessary for the furtherance of this Agreement. Senetek further agrees to bind its officers and employees, and any agents, representatives or third parties who have knowledge of or access to such
“Confidential” information to a similar obligation of confidentiality. In the event of termination of this Agreement, Senetek agrees to return any such “Confidential” materials or information to Signet and to cause any person to
whom such “Confidential” materials or information as been supplied to do likewise. 
  

 8 

 9. Governing Law and Arbitration; Venue 
  

	 	9.1	This Agreement shall be deemed made under, governed by and construed in accordance with the laws of the State of California, without giving effect to conflict of laws provisions
thereof. The parties agree that the party to this Agreement prevailing in an action arising from breach of this Agreement or of any of its provisions shall be entitled to all costs of such suit or action, including attorney’s fees.

  

	 	9.2	Any controversy or claim arising out of or relative to this Agreement or the breach thereof shall be settled by arbitration in San Francisco California, in accordance with the Rules
of the American Arbitration Association then obtaining, and judgment upon the award rendered by the arbitrator(s) may be enforced in either the courts of the State of California or the United States District Court for the District of California to
whose jurisdiction each of the parties hereby consents. All arbitrators appointed must be expert in the field, with at least one arbitrator sourced from the Licensing Executives Society. Nothing contained herein shall prevent the parties from
seeking injunctive or other equitable relief in the foregoing courts prior to arbitration. 

 10. General 
 10.1 In the event any proceeding is commenced to enforce this Agreement or otherwise relating to this Agreement, the prevailing party shall be entitled to
reasonable attorney’s fees and costs incurred in connection therewith. 
 10.2 This Agreement may be executed in one or more
counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument; however, this Agreement shall be of no force or effect until executed by both parties. 
 10.3 Captions and Section and Subsection headings used herein are for convenience only, and are not a part of this Agreement and shall not be used in
construing it. 
 10.4 Each of the parties agrees to execute and deliver such further documents and to cooperate in such manner as 

may be necessary to implement and give effect to the agreements contained herein. 
 10.5 This Agreement shall be binding upon and shall inure to the benefit of each party and its successors and permitted assigns. 
 10.6 If any provision of this Agreement, or the application thereof, is held to be invalid or unenforceable, the remainder of the Agreement shall continue
in full force and effect 
 10.7 The terms of this Agreement shall supersede the terms of any invoice, confirmation, purchase order or other

 commercial document of the parties. 
 10.8 No waiver by either party of any condition, or of any breach of any term, covenant, representation, or warranty contained in this Agreement, in any one or more instances, shall be deemed to be or construed as a further breach or a
waiver of any other condition or of any breach of any other term, covenant, representation, or 
 warranty. 
 10.9 This Agreement sets forth the entire agreement and understanding between the parties hereto respecting the subject matter hereof and supersedes all
prior oral discussions and writings between the parties. No modification, extension or waiver of this Agreement or any provision thereof shall be binding unless agreed to in writing by the parties . 
 10.10 For the purpose of all provisions of this Agreement requiring the giving of notice by either party to the other, notice shall be deemed to be given
when mailed by registered mail, postage prepaid, and sent to the addresses given below for Signet and Senetek. 
  

 9 

 The notices to Signet should be sent to the attention of 
 Dr Richard D. Gill, President and CEO 
 Signet Laboratories 
 180 Rustcraft Road 
 Dedham, Massachusetts 02026 
 The notices to Senetek should be sent to the attention of 
 Frank J. Massino, Chairman and CEO 
 Senetek PLC 
 620 Airpark Road 
 Napa, California 94558 
 IN WITNESS WHEREOF the representative parties hereto have executed this Agreement by their fully authorized officers on the date appearing below their signatures. 
  

					
		 	Signet Laboratories, Inc
			
	Date: 3-21-2005	 	By:	 	 /s/[ILLEGIBLE]

		 		 	[ILLEGIBLE] 
		 		 	EXEC. CHR., FOUNDER
		
		 	Senetek PLC
			
	Date: 3-8-2005	 	By:	 	 /s/ Bradley D. Holsworth

		 		 	Bradley D. Holsworth-CFO

  

 10 

 Exhibit A 
 Basic Agreement/License between Senetek and RFMH 
 AMENDMENT #2 
 Reference is hereby made to an Agreement by and between Research Foundation for Mental Hygiene, Inc. with a principal place of business in Albany NY
(Hereinafter referred to as RFMH) and Senetek PLC, a United Kingdom Company, whose principal office is located at 23 Place Street, London, SW1E SHW England, with an office located at 620 Airpark Road, Napa, California 94558 (hereinafter referred to
as “Senetek”) dated by Senetek July 21, 1994 and dated by RFMH July 12, 1994 (hereinafter referred to as the “Agreement”), as amended by Amendment #1 dated by Senetek August 1, 1995 and dated by RFMH July 28,
1995. RFMH and Senetek are sometimes collectively referred to herein as the “Parties”. 
 For valuable consideration, receipt and
sufficiency of which is hereby acknowledged, the parties hereby agree to amend the Agreement as follows: 
  

	 	1.	The following Section is hereby deleted: 

 5.3 Except for
the License maintenance fee (5.1), payments shall be payable as follows: 
  

	 	a.	Annually, starting with the January 1st
following the effective date of this Agreement and every January 1st thereafter until annual volume of net
sales of Licensed Product(s) reach *** 

  

	 	b.	Quarterly thereafter. 

  

	 	c.	Written reports and payment shall be made within 30 days of the period in this paragraph. 

  

	 	2.	In its place, the following shall be added: 

 5.3 Except
for the License maintenance fees (5.1), payments shall be payable as follows: 
  

	 	a.	Annually, starting with the January 1st
following the effective date of this Agreement, and every January 1st thereafter until annual volume of net
sales of Licensed Product(s) reach *** 

  

	 	b.	Quarterly thereafter. 

  

	 	c.	Written reports and payment shall be made within 60 days of the period in this paragraph. 

 The Parties ratify and confirm the Agreement save as the same may be changed by this amendment. 
  

					
		 	Research Foundation for Mental Hygiene, Inc.
			
	Date: 11/1/00 	 	By:	 	 /s/ Robert E. Burke 

		 		 	Managing Director
		
		 	Senetek PLC
			
	Date: 12/12/00 	 	By:	 	 /s/ Frank Massino 

		 		 	Frank Massino, President

 *** Confidential treatment has been requested 
  

 11 

 AMENDMENT #1 
 The Agreement between the Research Foundation for Mental Hygiene, Inc. and Senetek PLC executed July 21, 1994, is hereby amended for the purpose of allowing, from time to time, the licensing of new cell lines and
licensed product under this Agreement. 
  

	1.1	DEFINITIONS (is amended to include) 

  

	1.1a	“Licensed Cell Lines” (amended to include) 

 Licensed Cell Lines shall also include any cell line later licensed under this Agreement and appended to Appendix A by mutual written agreement of the parties. 
  

	2.3b	GRANT OF LICENSE (is amended to read) 

 For each
cell line licensed under this Agreement, starting one year after the effective date on which that cell line was licensed and included in Appendix A, and the effective date of cell lines licensed thereafter and appended to Appendix A, should the
Licensed Product sales for any cell line be less than *** for two (2) consecutive years, then at its sole discretion, RFMH may, by giving LICENSEE written notice, revoke the exclusivity of license provided for that cell line and
the license granted herein shall become nonexclusive. RFMH, for each licensed cell line for which exclusivity was so terminated, shall have the right to grant others world-wide license to possess, maintain, culture, and employ the cell line,
and to manufacture and sell the monoclonal antibodies produced therefrom in any form. 
  

	3.1	DELIVERY OF LICENSED CELL LINES (is amended to read) 

 RFMH shall supply LICENSEE with the Licensed Cell Lines included in Appendix A of this agreement within 30 days of the effective date of the Agreement. 
 RFMH shall, for any new cell lines licensed and appended to Apendix A after the effective date of this Agreement, supply those cell lines to
LICENSEE within 30 days of the effective date the new cell line(s) were appended to Appendix A. 
  

	4.1	EFFECTIVE DATE & TERM (is amended to read) 

 The effective date of this Agreement shall be the date of the last signatory to the Agreement. The effective date for each appendicy added to Appendix A, shall be the date of the last signatory to that appendicey. The term of this Agreement
shall, for each cell line included in Appendix A or appendicey to Appendix A, be ten (10) years from the effective date of the Agreement t-or those cell lines included in Appendix A and ten (10) years from the effective date of each appendicy
to Appendix A, unless terminated earlier in accordance with Articles 2.3b and 9.9. 
 *** Confidential treatment has been requested

  

 12 

	5.1	ROYALTIES (is amended to read) 

 During the term of
this Agreement, for each cell line licensed, on or after the effective date of this Agreement, LICENSEE shall pay to RFMH an annual maintenance fee of ***. The first payment for each such licensed cell line shall be made upon delivery
of that cell line by RFMH to LICENSEE and on that anniversary date thereafter. Said payments are non-refundable but are fully creditable against royalties. 
  

	9.9	TERMINATION (added to Agreement) 

 The license for
any cell line may be terminated in accordance with 2.3(b) 
 IT IS UNDERSTOOD AND AGREED that all other terms and conditions shall
remain in full force and effect. 
  

							
	SENETEK	 	 RESEARCH FOUNDATION FOR
     MENTAL HYGIENE, INC.

				
	By	 	 /s// Edward Curel
	 	By	 	 /s/ Patrick Furlong

	Title	 	Vice President	 	Title	 	Managing Director
	Date	 	August 1, 1995	 	Date	 	7/28/95

 *** Confidential treatment has been requested 
  

 13 

 AGREEMENT by and between Research Foundation for Mental Hygiene, Inc. located at 44 Holland
Avenue, Albany, New York 12229, hereinafter referred to as RFMH, and Senetek PLC, whose principal office is located at 23 Palace Street, London, SWIE SHW England, hereinafter referred to as LICENSEE or SENETEK. 
 W I T N E S S E T H: 
 WHEREAS,
RFMH under an agreement with the New York State Office of Mental Retardation and Developmental Disabilities (OMRDD) is authorized to enter into agreement and execute documents for the purpose of commercial development and marketing of inventions
and technology emanating from the research institutes of the (OMRDD), such agreements being subject to approval by the (OMRDD) and the Office of the State Controller and, 
 WHEREAS, RFMH is in possession of certain cell lines, described hereunder, which are capable of producing monoclonal antibodies reactive to beta amyloid proteins, and 
 WHEREAS, RFMH, in the public interest, and in accordance with its authority, desires to make these monoclonal antibodies available to the
scientific community for research and diagnostic purposes, and 
 WHEREAS, SENETEK desires to license from RFMH the rights to
produce and market said monoclonal antibodies to the scientific community for research and diagnostic purposes. 
 NOW THEREFORE, in consideration of
the above in accordance with the mutual promises and covenants contained herein the parties agree as follows: 
  

	I.	DEFINITIONS 

  

	 	1.1	“Licensed Cell Lines” are defined as the hybridoma cell lines developed and characterized by Drs. K.S. Kim, Henry Wisniewski and others at the New York State
Institute for Basic Research located at Staten Island, New York, which cell lines produce monoclonal antibodies reactive to beta amyloid proteins, and are designated 4G8 and 6E10 and described in Appendix A hereto, and any progeny or mutant thereof.

  

	 	1.2	“Licensed Product(s)” shall mean the monoclonal antibodies produced in any form by using the “Licensed Cell Line(s)”, whether pure, Fab fragment, ascites
fluid, tissue culture fluid, modified, or conjugated (ie., enzymes, biotin, florescent, or any other form). 

  

	 	1.3	“Net Sales” shall mean gross sales of Licensed Product(s) invoiced less, when billed separately: 

  

	 	(a)	Import, export, excise and sales taxes, and custom duties and freight; 

  

	 	(b)	Sales returns and allowances. 

  

 14 

	2.	GRANT OF LICENSE 

  

	 	2.1	RFMH hereby grants an exclusive worldwide license, to possess, maintain, culture and employ the Licensed Cell Line(s) exclusively for the purpose of manufacturing or having
manufactured for the LICENSEE the Licensed Product(s) and which Licensed Products(s) the LICENSEE shall sell commercially directly to the end user. The Licensed Cell Lines are to be sold only for invitro scientific research and
diagnostic purposes and shall never be sold for invivo use. This license does not include a right to transfer or sublicense any rights under this Agreement except as provided hereafter in Article 2.3. Senetek shall actively market the Licensed
Product in a manner consistent with industry practice 

  

	 	2.2	RFMH, during the term of this Agreement shall not license any other party the privileges granted by this license except as provided in 2.3. 

 

	 	2.3	Not withstanding 2.1 and 2.2: 

  

	 	a)	RFMH, however, shall retain the right to possess, culture and employ the Licensed Cell Lines and the antibodies produced therefrom for its own scientific purposes
including transferring necessary amounts of antibodies to research collaborators of RFMH free of all charges other than shipping and handling cost. Such collaborator shall be bound by an obligation to use these antibodies only for the scientific
collaboration with RFMH. 

  

	 	b)	Except for the first year of this agreement, should annual sales of the Licensed Product be less than *** for any two (2) consecutive years, then at its sole discretion,
RFMH may revoke the exclusivity of license provided in 2.1 and the license granted herein shall become nonexclusive. RFMH shall then have the right to grant others world-wide license to possess, maintain, culture and employ the cell
lines included as items 1 and 2 of Appendix A and licensed under this Agreement and to manufacture and sell the monoclonal antibodies produced therefrom in any form. 

  

	 	2.4	LICENSEE may contract with a third party to manufacture for it, the Licensed Product(s). Prior to any transfer of the Licensed Cell Line(s) to such third party, RFMH
shall have received a copy of contract 

 *** Confidential treatment has been requested 
  

 15 

 and approved the transfer of the Licensed Cell Line(s). The contract between LICENSEE and the
third party shall protect RFMH’s rights with regard to the Licensed Line(s) as though the contract had been between RFMH and the third party, including notification; 
  

	 	a)	that the Licensed Cell Line(s) transferred from LICENSEE to the third party is the sole property and confidential proprietary information of RFMH, and subject to the
same confidentiality requirements as are imposed on the LICENSEE, and may be transferred only back to the LICENSEE or RFMH; 

  

	 	b)	the Licensed Product(s) produced by the third party are solely for the purpose of providing them directly to LICENSEE; 

  

	 	c)	SENETEK shall certify annually to RFMH the compliance by third parties with the applicable terms of this Agreement. Such compliance shall include verification of third
party production and shipping records. 

  

	 	d)	the termination date of this License Agreement, and the obligations of the termination clause for return of the Licensed Cell Line(s) and Licensed Products as well as an accounting
for same. 

  

	3.	DELIVERY OF LICENSED CELL LINE(S) 

  

	 	3.1	RFMH shall supply LICENSEE with the Licensed Cell Line(s) within thirty (30) days of the effective date of this License Agreement. 

  

	 	3.2	For a period of six (6) months following the shipment of the Licensed Cell Lines, RFMH shall keep in storage a back-up supply of the cell lines so that they can be
resupplied to SENETEK in case of accidental loss of the cell lines originally supplied. 

  

	 	3.3	RFMH shall furnish SENETEK with micro photographs and other scientific data necessary for the marketing of the Licensed Product. RFMH shall present invoices to
LICENSEE for out-of-pocket costs incurred and LICENSEE shall, within 30 days, reimburse RFMH for same. 

  

	4.	EFFECTIVE DATE & TERM 

  

	 	4.1	The effective date of this License Agreement shall be the date of the last signatory and it shall continue for a period of ten (10) years from that date unless terminated
earlier in accordance with Article 9 hereunder. 

  

 16 

	5.	ROYALTIES 

  

	 	5.1	SENETEK shall, starting with the effective date of this Agreement and again on each Anniversary Date, until termination, pay to RFMH a license maintenance fee
of *** for each cell line licensed and shipped to LICENSEE. Said payments are non-refundable but are fully creditable against royalties. 

  

	 	5.2	In addition, SENETEK shall pay RFMH an earned royalty of *** of Net Sales. Earned royalties shall be accompanied by a written report as to the calculation of such
royalties detailed by sale of product(s) from each cell line and the form in which it is sold. 

  

	 	5.3	Except for the License maintenance fees (5.1), payments shall be payable as follows: 

  

	 	a)	Annually, starting with the January 1st following the effective date of this Agreement, and every January 1st thereafter until annual volume of net sales of Licensed
Product(s) reach ***. 

  

	 	b)	Quarterly thereafter. 

  

	 	c)	Written reports and payment shall be made within 30 days of the periods in this paragraph. 

  

	 	5.4	Payments shall be made in U.S. Dollars. 

  

	 	5.5	RFMH shall have the right to verify sales of Product made by LICENSEE. RFMH or its agent shall, upon reasonable notice, be given access to the records of
LICENSEE necessary for such verification. SENETEK shall monitor and certify to RFMH that the units of production and sales of the Licensed Product manufacturer. LICENSEE’s Agreement with any producer or manufacturer
shall reflect such rights. 

  

	 	5.6	Royalty and Reporting requirements are also subject to the Article 9., TERMINATION 

  

	6.	CONFIDENTIALITY 

 The Licensed Cell Line(s)
are the confidential and proprietary wholly owned property of RFMH and shall be used only for the purpose of manufacturing the Licensed Product. The cell lines may only be transferred to the manufacturer contracted by LICENSEE to
produce such Licensed Product. The LICENSEE shall be obligated by the confidentiality requirements hereunder: 
 1 - Licensed Cell
Lines shall be clearly marked “Confidential Information” 
 2 - Kept in a secure location 
 3 - Allowed access to only those individuals who have the need in order to fulfill the terms of this Agreement and are themselves obligated to the
confidentiality provisions herein. 
 *** Confidential treatment has been requested 
  

 17 

	7.	WARRANTIES & REPRESENTATIONS 

 RFMH makes no warranty whatsoever, whether expressed, or implied. Nothing in this Agreement, shall be construed as: 
  

	 	a)	A warranty or representation that any thing made, used, sold or otherwise disposed of under any license granted in this Agreement is or will be free of infringement, patent or
copyrights and trademarks of third parties. 

  

	 	b)	Conferring rights to use in advertising, publicity, trademark or any other medium the name RFMH, the State of New York, its institutes, or any of their employees,
representatives, trustees, officers and agents without prior written approval of RFMH. 

  

	 	c)	A warranty of the merchantability or fitness of the Licensed Product for any particular purpose. 

  

	 	d)	Allowing the LICENSEE any other rights to the Licensed Cell Lines or Licensed Product(s) other than what is licensed under this Agreement. 

  

	8.	INDEMNITY 

  

	 	8.1	LICENSEE agrees to indemnify and hold harmless RFMH, the State of New York, or any of their institutes, employees, representatives, trustees, officers and agents
against any and all claims of death, illness, personal injury, property damage and improper business practices arising out of the use of the Licensed Cell Line(s) and or Licensed Product. 

  

	 	8.2	RFMH, and the State of New York shall not be liable for any indirect special, consequential or other damages whatsoever, whether grounded in fact (including negligence)
strict liability, contract or otherwise. 

  

	 	8.3	LICENSEE shall at all times comply through insurance or self insurance with all statutory workers compensation and employee liability requirements covering any and all
employees with respect to activities performed under this Agreement. 

  

	9.	TERMINATION 

  

	 	9.1	LICENSEE may terminate this Agreement by giving RFMH notice in writing at least 90 days n advance of the effective date of termination provided that LICENSEE
shall thereupon cease use and sale of Licensed Cell Line(s) and Licensed Product(s). 

  

 18 

	 	9.2	RFMH may terminate this Agreement if LICENSE is in breach of any provision whereof and LICENSEE fails to remedy any such breach within sixty (60) days
after written notice thereof by RFMH. Termination of this Agreement for any reason shall not release either party from any obligations theretofore accrued. 

  

	 	9.3	The failure on the part of either party hereto to exercise or enforce any right conferred upon it hereunder shall not be deemed to be a waiver of such right nor operate to bar the
exercise or enforcement thereof in the future. 

  

	 	9.4	If anything written in this Agreement is in violation of any applicable laws or regulations or is unenforceable or void for any reason whatsoever, then such part shall be
inoperative while the remainder of the Agreement shall remain binding upon the parties. 

  

	 	9.5	Surviving any termination are; 

  

	 	a)	Any cause of action or claim of LICENSEE or RFMH, accrued or to accrue because of any breach by the other party 

  

	 	b)	Payment of accrued royalties 

  

	 	c)	The provisions of Articles 6., CONFIDENTIALITY 

  

	 	9.6	Concurrent with notice of termination by LICENSEE or RFMH, LICENSEE shall return to RFMH or destroy, with written notification to RFMH of such
destruction, all Licensed Cell Line(s) in its possession and shall require the same any of its manufacturer. Any Product(s) in the inventory of the LICENSEE or its contracted product manufacturer may be sold for a period not to exceed three
(3) months. These sales shall be subject to the royalty and reporting requirements of this Agreement. 

  

	 	9.7	LICENSEE also agrees to make a report within 120 days of the termination of this Agreement, stating in such report the number, description and net sales of all
Licensed Product(s) made, sold, or otherwise disposed of and upon which royalties are payable but which were not previously reported to RFMH. 

  

	 	9.8	Notwithstanding 9.1 and 9.2, at least thirty (30) days prior to filing a petition in bankruptcy, each party must inform the other of its intention to file the petition
or of another’s intention to file an involuntary petition in bankruptcy. The party so informed may terminate this Agreement immediately and all royalties due thereunder shall become immediately due and payable. Further, failure to conform to
this requirement shall be deemed a material, pre-petition, incurable breach, and this Agreement shall automatically terminate, and all royalties due thereunder shall become immediately due and payable. 

  

 19 

	10.	NOTICES 

 All notices under this Agreement
shall be deemed to have been fully given when given in writing and deposited in the postal system of the country in which the notice originates and addressed as follows:  
 To RFMH: 
 Research Foundation for Mental Hygiene, Inc. 
 44 Holland A venue Albany, NY 12229 
 ATTN: Patrick L. Furlong, Managing Director 
 To LICENSEE:: 
 Senetek PLC 
 62A Weldon Parkway 
 Maryland Heights, MO 63043 
  

	11.	MISCELLANEOUS 

  

	 	a)	This Agreement shall be construed and interpreted in accordance with the laws of the State of New York. 

  

	 	b)	This Agreement represents the entire agreement between the parties hereto and may be changed only by a written amendment signed by both parties. 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement. 
  

							
	SENETEK	  	 RESEARCH FOUNDTION FOR
 MENTAL
HYGIENE, INC.

				
	By	 	 //s// Gerlof Homan
	  	        By	 	 //s// Patrick Furlong

	Title	 	CEO, Senetek	  	        Title	 	Managing Director
	Date	 	7/21/94	  	        Date	 	7/18/94

  

 20 

 APPENDIX A 
 ANTI-AMYLOID BETA MONOCLONAL ANTIBODIES 
  

	1.	4G8 IgG2b Specific to amino acid residues 17-24 

  

	2.	6E10 IgG1 Specific to amino acid residues 1-16 

  

 21 

 APPENDIX A-1 
 RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC. 
 and 
 SENETEK PLC 
 MONOCLONAL ANTIBODY
LICENSE 
 AGREEMENT 
 The following monoclonal antibody described herein is hereby annexed to, and made part of the Agreement between the parties executed 7/21/94, and amended on 7/31/95. 
 5-25 Reactive to PHF 
  

							
	SENETEK	 	 RESEARCH FOUNDTION FOR
 MENTAL
HYGIENE, INC.

				
	By	 	 //s// Edward Curley 
	 	        By	 	 //s// Patrick Furlong

	Title	 	Vice President	 	        Title	 	Managing Director
	Date	 	August 1, 1995	 	        Date	 	7/28/95

  

 22 

 APPENDIX A-2 
 RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC. 
 and SENETEK PLC 
 MONOCLONAL ANTIBODY LICENSE 
 AGREEMENT 
 The following monoclonal antibodies described herein are hereby annexed to, and made part of the Agreement between the parties
executed 7/21/94, and amended on 7/31/95 
 3-39 Reactive to PHF 
 3F4 Reactive to Prior PrP (human and hamster) 
  

							
	SENETEK	 	 RESEARCH FOUNDTION FOR
 MENTAL
HYGIENE, INC.

				
	By	 	 //s// Edward Curley 
	 	By	 	 //s// Patrick Furlong 

	Title	 	Vice President 	 	Title	 	Managing Director 
	Date	 	August 30, 1995 	 	Date	 	8/22/95 

  

 23 

 APPENDIX A-3 
 RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC. 
 And SENETEK PLC 
 ANTIBODY LICENSE 
 AGREEMENT

 Amendment No. 1 Article 1. 1a, executed August 1, 1995, provides that “Licensed Cell Lines shall include any cell line later licensed under
this Agreement and appended to Appendix A by mutual agreement of the parties”. Accordingly, the parties hereto agree to include under the terms of the Agreement executed July 21, 1994, and amendments thereto, the following cell lines and
licensed product: 
  

					
	Tau p4	  	Mab4H6	  	Mab5C7
	ERAB	  	Mab5F3	  	Mab10D12
	Synuclein	  	Mab4B12	  	Mab4D6
	Apo E	  	MabE6D7	  	MabD6E10
	Spectrin	  	Mab17C7	  	
	Spectrin Binding Protein	  	MabD8B7	  	
	Spectrin Binding Protein	  	Mab4E2	  	
	Sheep PrP Clone	  	4B4	  	

  

							
	SENETEK	 	 RESEARCH FOUNDTION FOR
 MENTAL
HYGIENE, INC.

				
	By	  	 //s// Corena Michnevich
	 	        By	 	 //s// Robert E Burke

	Title	  	Vice President	 	        Title	 	Managing Director
	Date	  	July 2, 2001	 	        Date	 	7/11/01

  

 24 

 Exhibit B 
 Extension of Basic Agreement/License until September 30th 2005

 Amendment #3 
 Extension of Basic Agreement/License until September 30th 2005 
 The Agreement between the Research Foundation for Mental Hygiene, Inc. and Senetek PLC executed July 21, 1994 is herby amended for the purpose of extending the
license on the three original licensed cell lines. 
 The end date of this Agreement shall, for cell lines 4G8 and 6E10, be extended from
July 20, 2004 to September 30, 2005. The end date of this Agreement shall, for cell line 525, be extended from July 31, 2005 to September 30, 2005. Therefore, on September 30, 2005 the Agreement on the following cell lines
shall expire: 4G8, 6E10, 525, 3-39 and 3F4. 
 MILESTONES 
  

	 	1.	In consideration for the extension of the License to September 30, 2005, Senetek agrees to pay the RFMH a minimum royalty of *** (US dollars) for the period 7/1/04 to 6/30/05.
Any shortfall of the minimum annual royalty will be paid in connection with the royalties for the quarter ended June 30, 2005. 

  

	 	2.	By December 31, 2004, Senetek shall submit a proposal to the RFMH outlining Senetek’s plans for the manufacturing, packaging, promotion and sales of the licensed cell
lines through July 10, 2011. Such plan shall be subject to the review and approval of the RFMH. If such plan is approved by RFMH, the Agreement for the cell lines noted above will be extended to July 10, 2011. 

 IT IS UNDERSTOOD AND AGREED that all other terms and conditions shall remain in full force and effect. 
  

							
	 Research Foundation for Mental
 Hygiene, Inc.
	 	Senetek PLC
				
	By:	 	 /s/ ROBERT E. BURKE
	 	By:	 	 /s/ FRANK J. MASSINO

		 	Robert E. Burke, Managing Director	 		 	Frank J. Massino, Chairman & CEO
	Date:	 	May 10, 2004	 	Date:	 	May 6, 2004

 *** Confidential treatment has been requested 
  

 25 

 Exhibit C 
 Cell Line Products 
  

							
		 	4G8	 		 	
		 	6E10	 		 	
		 	3F4	 		 	
		 	1E11	 		 	
		 	2H4	 		 	
		 	4D6	 		 	
		 	4B12	 		 	
		 	7D9	 		 	
		 	4B4	 		 	
		 	5-25	 		 	
		 	3-39	 		 	
		 	17C7	 		 	
		 	D8B7	 		 	
		 	4E2	 		 	
		 	D6E10	 		 	
		 	E6D7	 		 	
		 	10D12	 		 	
		 	5F3	 		 	
		 	4H6	 		 	
		 	5C7	 		 	

 The expiration date of Cell lines 4G8, 6E10, 3F4, 5-25 and 3-39 is currently September 30, 2005. The license
for these cell lines between Senetek and RFMH is expected to be extended to July 2011 upon execution of this agreement. Cell lines 1E11, 2H4 and 7D9 are expected to be added to the Senetek-RMH agreement and have an expiration date of July 2011
upon execution of this agreement. All other cell lines in Exhibit C are under licensee between Senetek and RFMH and expire in July 2011. 
  

 26 

 Schedule I 
 Signet Kits 
 1-42 ELISA kit 
  

																					
	 Component
	  	# per
kit	  	unit	  	 cost per
 unit
	  	cost per
kit	  	Cost %	  	Component
Price	  	 Component
List
	  	 Component
 Discounted
	  	 Total
 IBRDD
	  	 Kit
 List

	Plate Coating	  	1	  	ea	  	***	  	***	  	***	  		  		  		  		  	
	4G8*	  	45	  	ug	  	***	  	***	  	***	  	***	  	***	  	***	  		  	
	6E10*	  	30	  	ug	  	***	  	***	  	***	  	***	  	***	  	***	  		  	
	plate sealer	  	3	  	ea	  	***	  	***	  	***	  		  		  		  		  	
	wash (2X)	  	300	  	ml	  		  	***	  	***	  		  		  		  		  	
	standard diluent	  	3	  	ml	  		  	***	  	***	  		  		  		  		  	
	1-42 standard	  	20	  	ug	  	***	  	***	  	***	  		  		  		  		  	
	1-42 antibody	  	1	  	ug	  	***	  	***	  	***	  	***	  	***	  	***	  	***	  	***
	Gt-anti rab HRP	  	1	  	ug	  		  	***	  	***	  		  		  		  		  	
	OPD	  	2	  	tab	  	***	  	***	  	***	  		  		  		  		  	
	OPD diluent	  	24	  	ml	  		  	***	  	***	  		  		  		  		  	
	Hydrogen peroxide	  	100	  	ul	  	***	  	***	  	***	  		  		  		  		  	
	Stop solution	  	15	  	ml	  	***	  	***	  	***	  		  	Component Price for 4G8 and 6E10 based on *** per mg = *** per ug
	250 ml bottle	  	1	  	ea	  	***	  	***	  	***	  		  	Component List = Col H X Col B
	15 ml brown bottle	  	3	  	ea	  	***	  	***	  	***	  		  	Component Discounted represents standard *** discount
	clear vials	  	3	  	ea	  	***	  	***	  	***	  		  	Component Price List for 1-42 based on 50 ug = *** or *** per ug
	brown glass	  	1	  	ea	  	***	  	***	  	***	  		  	Percentage Ab to list total is *** 
	Foam	  	1	  		  		  	***	  	***	  		  	Standard rate is *** + *** = ***
	Box	  	1	  		  		  	***	  	***	  		  		  		  		  	
	Labor	  	2	  	hr	  	***	  	***	  	***	  		  	Customers who purchase 1 of each kit -*** per kit (BioSource compare)
	                     
 *  Cost per unit excludes royalty
	  		  		  	Total	  	***	  	***	  		  		  		  		  	
		  		  		  	Antibody	  	***	  		  		  		  		  		  	
		  		  		  	% antibody	  	***	  		  		  		  		  		  	
											
	1 -40 ELISA kit	  		  		  		  		  		  		  		  		  		  	
											
	Plate coating	  	1	  	ea	  	***	  	***	  	***	  		  		  		  		  	
	6E10	  	60	  	ug	  	***	  	***	  	***	  	***	  	***	  	***	  		  	
	plate sealer	  	3	  	ea	  	***	  	***	  	***	  		  		  		  		  	
	wash (2X)	  	300	  	ml	  		  	***	  	***	  		  		  		  		  	
	Standard diluent	  	3	  	ml	  		  	***	  	***	  		  		  		  		  	
	1-40 standard	  	20	  	ug	  	***	  	***	  	***	  		  		  		  		  	
	1-40 antibody	  	1	  	ug	  	***	  	***	  	***	  	***	  	***	  	***	  		  	
	Gt-anti rab HRP	  	1	  	ug	  		  	***	  	***	  		  		  		  		  	
	OPD	  	2	  	tab	  	***	  	***	  	***	  		  		  		  		  	
	OPD diluent	  	24	  	ml	  		  	***	  	***	  		  	Component Price for 6E10 based on *** per mg = *** per ug
	Hydrogen peroxide	  	100	  	ul	  	***	  	***	  	***	  		  	Component List = Col H x Col B
	Stop solution	  	15	  	ml	  	***	  	***	  	***	  		  	Component Discounted represents standard *** discount
	250 ml bottle	  	1	  	ea	  	***	  	***	  	***	  		  	Component Price List for 1-40 based on 50 ug = *** or *** per ug
	15 ml brown bottle	  	3	  	ea	  	***	  	***	  	***	  		  		  		  		  	
	clear vials	  	3	  	ea	  	***	  	***	  	***	  		  		  		  		  	
	brown glass	  	1	  	ea	  	***	  	***	  	***	  		  		  		  		  	
	Foam	  	1	  		  		  	***	  	***	  		  		  		  		  	
	Box	  	1	  		  		  	***	  	***	  		  		  		  		  	
	Labor	  	2	  	hr	  	***	  	***	  	***	  		  		  		  		  	
		  		  		  	Total	  	***	  		  		  		  		  		  	
		  		  		  	Antibody	  	***	  		  		  		  		  		  	
		  		  		  	% antibody	  	***	  		  		  		  		  		  	

 *** Confidential treatment has been requested 
  

 27 

 Schedule II 
 Approved Non-End User Customers 
  

			
	 Company
	  	 Nature of Distributor Pursuant to Section 6.1(v)

	Abcam Ltd	  	(a) and (b)
	Alexis Corporation	  	(a) and (b)
	Anse Trading Corp	  	(a) and (f)
	Atom S. A.	  	(a) and (f)
	BioCat GmbH	  	(a)
	Bioqoute Ltd	  	(a)
	BioValley Chemistry & Bio	  	(a) and (f)
	Cedarlane Laboratories	  	(b)
	Cosmo Bio Co. LTD	  	(a) and (f)
	ID Labs Inc.	  	(a) and (b)
	Immuno Diagnostic OY	  	(a)
	Jomar Diagnostics	  	(a)
	Novakemi ab	  	(a)
	Onwon Trading	  	(a)
	Pharmatrade Ltd	  	(a)
	Sanbio bv	  	(a)
	Wako Chemicals USA	  	(a) and (f)
	Watson Biotechnology Co.	  	(a)
	Biosource International	  	(d) and (f)
	Chemicon International	  	(a), (b) and (f)
	Biodesign	  	(a), (b) and (f)
	EMD Biosciences	  	(a) and (b)
	Ciphergen Biosystems, Inc	  	(e)
	Ciphergen Biosystems, Symbion	  	(e)
	Fisher Scientific	  	(c)
	Interchim	  	(a)
	Nacali Tesque	  	(a) and (f)
	Oxford Biotechnology Ltd-(Division of Serotec)	  	(a)
	Serotec	  	(a) and (b)
	Proteoogenix SA	  	(a)
	Sanbio GMBH	  	(a)
	Sigma Chemical Company	  	(a), (b) and (f)
	VWR International	  	(c) and (f)
	VWR Scientific Products	  	(c) and (f)

  

 28

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00102-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00102-of-00352.parquet"}]]